Register for access to the Endpoints hub and theater and pick up your credentials/badges. All attendees require a name badge worn at all times

Endpoints News founding editor John Carroll will sit down with longtime Pfizer CSO Mikael Dolsten to talk about Pfizer’s pipeline, what he’s learned on the job about preclinical research and development and what’s ahead for the pharma giant in drug development and deals.

The drug industry's appetite for new assets hasn't slowed down. Top business development execs will give their outlook on the year, what they're looking for and how they see the market.

Not many biotechs went public in 2023. And of those that did, not many have had a great time of it. Apogee is the exception and our panel will offer a behind-the-scenes look at their decision to enter the market and what life is like as a young public company.

The founder of one of biopharma's most prolific company creators will share his outlook for the year in an interview with our executive editor.

Catalent CEO Alessandro Maselli will be back at the big JPM healthcare confab to talk with Endpoints News founder John Carroll about their top predictions of what’s coming up for the biotech industry in 2024. The stakes couldn’t be higher as the industry grapples with headwinds and new opportunities in a gale of market forces. Two top observers share their thoughts on the year ahead.

The industry has long discussed the promise of technology and the acceleration it provides in scientific advancement and across the industry value chain. However, the promise of its impact has yet to fully be realized. This discussion will outline the keys to unleashing this promise and the implications and actions to be taken by the biopharmaceutical companies across the industry.

Elliott has been behind many of 2023's highest-profile healthcare investments, including multiple activist engagements and taking Syneos Health private. What has made large healthcare companies such interesting investment opportunities for firms like Elliott? What’s Elliott’s investing strategy in healthcare? And what should companies expect when an activist calls?

AI is predicted to transform the way drugs are made, from discovery to clinical trials to market. But beyond the initial hype and early adoption, where has AI made meaningful contributions to R&D? How does it help drug developers advance science? Endpoints publisher Arsalan Arif is convening a panel of leading experts to discuss the state of AI in the pharmaceutical landscape and the outlook for 2024. How does AI impact the drug pipeline, from the early steps of discovery to reducing trial failure rate?

Almost every major biopharma deal in 2023 had Centerview’s name attached to it. And much of the time, Eric Tokat was the banker making those deals happen. Hear his outlook for 2024, how transactions are getting done and what’s placed his firm at the center of so much action.

Carolyn Bertozzi’s discoveries around bioorthogonal chemistry won the Nobel Prize in Chemistry in 2022 and are at the heart of new therapies being tested in patients. Join us as we discuss what inspires her and where she sees the next big advances.

Register for access to the Endpoints hub and theater and pick up your credentials/badges. All attendees require a name badge worn at all times.

Merck delivered oncology's biggest success of the 2010s. But what comes next? We'll discuss Merck's foray into immunology, its priorities for 2024, the IRA's influence on R&D choices and much more.

After a decade of progress in oncology, there's still much to be done. Our experts will talk through where cancer innovation is going, new targets and the data we'll be watching through the rest of the 2020s.

How does a pharma transaction get done? We'll hear from AstraZeneca about several recent deals and the strategic approach behind them.

It wasn't easy to raise capital in 2023. But some startups not only did so, they thrived. Get a candid look at the pitch, the technology and the promise behind one of last year's high-profile rounds.

Our panelists have seen the worst, and made it through to the other side. Join us for downturn survival school as our panelists talk about what sets apart the ones who make it through tough times.

Marianne De Backer was well known as one of the industry’s top dealmakers when she was tapped for the CEO’s job at Vir Biotechnology. Now the former Bayer and J&J exec has a broad remit and a host of objectives on R&D in infectious diseases — and beyond. She’ll sit down with Endpoints founding editor John Carroll to talk about being the CEO, leadership in biotechnology and what plans she’s making as we enter 2024.

Join us for a look at how AI, machine learning and generative technologies are actually being applied inside drugmakers' labs. We'll explore how new technologies are being used, their implications, how they intersect with regulatory and IP issues and how this fast-changing field is likely to evolve.

Walgreens hired a new CEO in October 2023. In an exclusive conversation with Endpoints News, the pharmacy giant's new leader Tim Wentworth breaks down what the company has in store for 2024.

Merdad Parsey will join Executive Editor Drew Armstrong for a discussion about the future of HIV treatment and prevention, the company's goals in the oncology space and more.

Our journalists wrap up by sharing their takeaways from the conference and their best guesses for the year ahead.